Prostaglandin E2-loaded microspheres as strategy to inhibit phagocytosis and modulate inflammatory mediators release

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 70, Issue 3, 2008, Pages 784-790

  Nicolete, Roberto ^a   Lima, Karla de Melo ^b   Júnior, José M R ^b   Jose, Peter J ^c   Sanz, María Jesús ^c,d   Faccioli, Lúcia Helena ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Nanocore Biotecnologia Ltda   (Brazil)

^c UNIVERSITY OF VALENCIA   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Biodegradable microspheres; Endothelial cells; Inflammatory mediators; Phagocytosis; Prostaglandin E2

Indexed keywords

MICROSPHERE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; BIODEGRADABILITY; DRUG FORMULATION; DRUG RELEASE; DRUG UPTAKE; EMULSION; ENCAPSULATION; ENZYME IMMUNOASSAY; EVAPORATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHAGOCYTOSIS; SEPSIS; SOLVENT EXTRACTION; SYNTHESIS;

ANIMALS; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; CHEMOKINE CCL2; DELAYED-ACTION PREPARATIONS; DINOPROSTONE; DISEASE MODELS, ANIMAL; DRUG COMPOUNDING; EMULSIONS; ENDOTHELIAL CELLS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION MEDIATORS; MACROPHAGES, PERITONEAL; MICE; MICROSPHERES; NITRIC OXIDE; OILS; PARTICLE SIZE; PHAGOCYTOSIS; SEPSIS; SOLUBILITY; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; WATER;

EID: 54949115799     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.06.019     Document Type: Article

References (33)

1. Phipps R.P., Stein S.H., and Roper R.L. A new view of prostaglandin E regulation of the immune response. Immunol. Today 12 (1991) 349
2. H Lee S., Soyoola E., Chanmugam P., Hart S., Sun W., and Hwang D. Selective expression of mitogen inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J. Biol. Chem. 267 (1992) 25934-25938
3. Hempel S.L., Monick M.M., and Hunninghake G.W. Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. J. Clin. Invest. 93 (1994) 391-396
4. Demasi M., E Caughey G., James M.J., and G Cleland L. Assay of cyclooxygenase-1 and 2 in human monocytes. Inflamm. Res. 49 (2000) 737-743
5. 2 and of agents that raise cAMP levels on macrophage activation induced by interferon (IFN)-γ and TNF-α. J. Leukoc. Biol. 58 (1995) 217-224
6. Dooper M.M., Wassink L., M'Rabet L., and M Graus Y. The modulatory effects of prostaglandin-E on cytokine production by human peripheral blood mononuclear cells are independent of the prostaglandin subtype. Immunology 107 (2002) 152-159
7. Taffet S.M., and Russell S.W. Macrophage-mediated tumor cell killing: regulation of expression of cytolytic activity by prostaglandin E. J. Immunol. 126 (1981) 424-427
8. Vogel S.N., Weedon L.L., Oppenheim J.J., and Rosenstreich D.L. Defective Fc-mediated phagocytosis in C3H/HeJ macrophages: correction by cAMP agonists. J. Immunol. 126 (1981) 441-445
9. 2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin production and down-regulation of transferrin receptor expression. J. Immunol. 135 (1985) 1172-1179
10. 2, which inhibits IgM secretion by peritoneal B-1a cells. J. Immunol. 154 (1995) 5630-5636
11. Weissmann G. Prostaglandins as modulators rather than mediators of inflammation. J. Lipid Mediat. 6 (1993) 275-286
12. Zurier R.B., and Quagliata F. Effect of prostaglandin E1 on adjuvant arthritis. Nature 234 (1971) 304-305
13. Eierman D.F., Yagami M., Erme S.M., Minchey S.R., Harmon P.A., Pratt K.J., and Janoff A.S. Endogenously opsonized particles divert prostanoid action from lethal to protective in models of experimental endotoxemia. Proc. Natl. Acad. Sci. USA 92 (1995) 2815-2819
14. Gilroy D.W., Colville-Nash P.R., Willis D., Chivers J., Paul-Clark M.J., and Willoughby D.A. Inducible cyclooxygenases may have anti-inflammatory properties. Nat. Med. 5 (1999) 698-701
15. Chappey O., Wautier M.P., Boval B., and Wautier J.L. Endothelial cells in culture: an experimental model for the study of vascular dysfunctions. Cell Biol. Toxicol. 12 (1996) 199-205
16. Minami T., and Aird W.C. Endothelial cell gene regulation. Trends Cardiovasc. Med. 15 (2005) 174-184
17. 2 stimulates angiogenesis by activating the nitric oxide/cGMP pathway in human umbilical vein endothelial cells. Exp. Mol. Med. 37 (2005) 588-600
18. Bustos M., Coffman T.M., Saadi S., and Platt J.L. Modulation of eicosanoid metabolism in endothelial cells in a xenograft model: role of cyclooxygenase-2. J. Clin. Invest. 100 (1997) 1150
19. Camacho M.J., Lopez-Belmonte J., and Vila L. Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygeanse-2 expression and prostaglandin I synthase activity. Circ. Res. 83 (1998) 353
20. Eldridge J.H., Staas J.K., Meulbroek J.A., Tice T.R., and Gilley R.M. Biodegradable and biocompatible poly (dl-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect. Immun. 59 (1991) 2978-2986
21. Lima K.M., and Rodrigues Jr. J.M. Poly-dl-lactide-co-glycolide microspheres as a controlled release antigen delivery system. Braz. J. Med. Biol. Res. 32 (1999) 171-180
22. Lima K.M., Silva C.L., and Rodrigues Jr. J.M. Microesferas biodegradáveis: uma nova alternativa para administração de vacinas de DNA vol. 12 (2000), Academic Press, Brasília pp. 10-130
23. 4-loaded biodegradable microspheres. Prostaglandins Other Lipid Mediat. 83 (2007) 121-129
24. Niwa T., Takeuchi H., Hino T., Kunou N., and Kawashima Y. Preparation of biodegradable nanospheres of water-soluble and insoluble drugs with d-l-lactide/glycolide copolymer by a novel emulsification solvent diffusion method, and drug release behavior. J. Control. Release 25 (1993) 89-98
25. Birnbaum T.D., Kosmala D.J., Henthorn B.D., and Peppas-Brannon L. Controlled release of 17-β-estradiol from PLGA microparticles: the effect of organic phase solvent on encapsulation and release. J. Control. Release 65 (2000) 375-387
26. Jaffe E.A., Nachman R.L., Becker C.G., and Minick C.R. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J. Clin. Invest. 52 (1973) 2745-2756
27. Baker C.C., Chaudry I.H., Gaines H.O., and Baue A.E. Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 94 (1983) 331
28. Bazile D.V., Ropert C., Huve P., Verrechia T., Marland M., Frydman A., Veillard M., and Spenlehauer G. Body distribution of fully biodegradable 14C-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials 13 (1992) 1093-1102
29. Powell W.S., Wang L., Khanapure S.P., Manna S., and Rokach J. High-pressure liquid chromatography of oxo-eicosanoids derived from arachidonic acid. Analytical Biochemistry 247 (1997) 17-24
30. Steffenrud S., Borgeat P., Evans M.J., and Bertrand M.J. Mass spectrometry of prostaglandins leukotrienes and steroids as their allyldimethylsilyl ether derivatives. Biomed. Environ. Mass Spectrom. 13 (1986) 657-661
31. Aroonrerk N., Suksamrarn A., and Kirtikara K. A sensitive direct ELISA for detection of Prostaglandin E2. J. Immunoassay Immunochem. 28 (2007) 319-330
32. Myers S.I., Wang L., and Myers D.J. Loss of renal function and microvascular blood flow after suprarenal aortic clamping and reperfusion (SPACR) above the superior mesenteric artery is greatly augmented compared with SPACR above the renal arteries. J. Vas. Surg. 45 (2007) 357-366
33. Gross S., Tilly P., Hentsch D., Vonesch J.L., and Fabre J.E. Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors. J. Exp. Med. 204 (2007) 311-320